Whether it is new and groundbreaking research results, university topics or events – in our press releases you can find everything you need to know about the happenings at Ƭ. To subscribe, just send an email to ott@pvw.uni-frankfurt.de
Theodor-W.-Adorno Platz 1
60323 Frankfurt
presse@uni-frankfurt.de
International study led by Ƭ Frankfurt sheds light on previously unknown interaction
An international team led by Ƭ Frankfurt has identified an intracellular sensor that monitors the quality of so-called MHC-I molecules, which help the immune system recognize and kill harmful cells, including tumor cells. The sensor ensures that defective MHC-I molecules remain inside the cell, where they are eventually degraded. Surprisingly, a lack of this quality assurance can lead to more MHC-I molecules reaching the surface of cancer cells, triggering a stronger immune response against the tumor.
FRANKFURT. It is comparatively easy to tell a cell's state of health: On their surface, cells present fragments of almost all the proteins they contain inside. This means the immune system can directly recognize whether a cell has been infected by a virus or has been dangerously altered by a mutation.
Countless molecular “radio masts" – the MHC-I molecules – are responsible for presenting these fragments. They are assembled inside the cell and then transported to the membrane, the lipid layer surrounding the cell. Here, the masts are anchored such that the cargo faces outside and can be detected by troops of the immune system constantly patrolling the body. If these troops detect harmful molecules being presented on the MHC-I radio masts, they kill the relevant cell. A requirement, however, is that the masts themselves are fully functional; otherwise, there is a risk that this mechanism will not work and harmful cells escape the immune system. “We have now discovered a sensor inside the cell that ensures that only functional MHC-I molecules are transported to the plasma membrane, while the defective units are eliminated," explains Dr. Lina Herhaus, who until recently conducted research on this topic at Ƭ's Institute of Biochemistry II and is now leading an independent research group at Braunschweig-based Helmholtz Centre for Infection Research.
Cells continuously produce a large number of proteins to sustain their manifold functions. If errors occur during this process, the affected molecules are usually eliminated. Specialized receptors recognize defective proteins and route them to mini garbage bags, where they are broken down. “As part of our study, we searched for yet unknown receptors and came across a protein called IRGQ, which is specifically responsible for ensuring the quality control of the MHC-I radio masts," says Herhaus.
The researchers used genetic interference to suppress the production of IRGQ. The result: defective radio masts accumulated in the cells, some of which were also incorporated into the cell membrane, together with their functional counterparts. “You would actually expect cells without IRGQ to trigger a weaker immune response. However, this is obviously not the case: Having analyzed various human tumors, we found that less IRGQ was associated with a better survival rate of patients with liver cancer," explains Prof. Ivan Đikić from the Institute of Biochemistry II, who co-led the study with Herhaus. The patient data was also confirmed in an experimental liver cancer mouse model: In animals without IRGQ, the immune system attacked tumor cells much more aggressively; as a result, the rodents without IRGQ survived the cancer significantly longer.
IRGQ could represent a target structure for new drugs, at least for liver cell carcinomas – the world's second most deadly type of cancer. “We have found a new mechanism by which tumor cells evade the immune system. In further studies, we will now examine IRGQ's influence on other types of cancer," emphasizes Đikić. “Our findings could be used in future to develop new therapies for liver cancer. One example would be to use drugs to target IRGQ for degradation and thereby stimulate the immune response against the cancer."
Irrespective of this, the newly discovered mechanism is also exciting for basic research. “We want to find out how important IRGQ is for the functioning of the immune system in general, including during viral infections," says Herhaus. “The results of our study raise a whole series of interesting questions, the answers to which can deepen our understanding of the body's immune defense."
Publication: Lina Herhaus, Uxía Gestal-Mato, Vinay V. Eapen, Igor Mačinković, Henry J. Bailey, Cristian Prieto-Garcia, Mohit Misra, Anne-Claire Jacomin, Aparna Viswanathan Ammanath, Ivan Bagarić, Jolina Michaelis, Joshua Vollrath, Ramachandra M. Bhaskara, Georg Bündgen, Adriana Covarrubias-Pinto, Koraljka Husnjak, Jonathan Zöller, Ajami Gikandi, Sara Ribičić, Tobias Bopp, Gerbrand J. van der Heden van Noort, Julian D. Langer, Andreas Weigert, J. Wade Harper, Joseph D. Mancias, Ivan Ðikić: IRGQ-mediated autophagy in MHC-I quality control promotes tumor immune evasion. Cell (2024),
Participating institutions:
Institute of Biochemistry II, Ƭ Frankfurt
Dana-Farber Cancer Institute, Harvard Institutes of Medicine
Department of Cell Biology, Harvard Medical School
Institute of Biochemistry I, Universitätsmedizin Frankfurt
Buchmann Institute for Molecular Life Sciences, Ƭ Frankfurt
Max Planck Institute of Biophysics, Frankfurt
University Medical Center, Johannes Gutenberg University Mainz
Department of Cell and Chemical Biology, Leiden University Medical Center
Images for download:
Captions:
1. Cells: Once cells' quality control mechanism is activated, IRGQ (red) accumulates in special cell organelles, the lsysosomes (green). This is also where the degradation of the non-functional MHC-I molecules takes place. Photo: Dr. Lina Herhaus, Ƭ Frankfurt
2. IRGQ-Structure (pink/orange) IRGQ is anchored via another protein (gray) in the membrane of the “garbage bags" in which the non-functional MHC-I molecules are packaged. The bags later fuse with the lysosomes, which initiates the degradation of the molecules. Image: Henry Bailey, Ƭ Frankfurt
Further information
Professor Ivan Ðikić
Institute of Biochemistry II
and Buchmann Institute for Molecular Life Sciences
Ƭ Frankfurt
Tel: +49 (0) 69 6301-5964
dikic@biochem2.uni-frankfurt.de
Lina Herhaus, Ph.D.
Group Leader - Immune Signaling
HZI - Helmholtz-Zentrum für Infektionsforschung GmbH
Lina.herhaus@helmholtz-hzi.de
Twitter/X: @goetheuni @IBC2 @Helmholtz_HZI
Editor: Dr. Markus Bernards, Science Editor, PR & Communication Office, Theodor-W.-Adorno-Platz 1, 60323 Frankfurt, Tel: +49 (0) 69 798-12498, bernards@em.uni-frankfurt.de
Ƭ adopts paper on the tension between academic freedom, freedom of expression and social responsibility
On the occasion of its 110th anniversary, Ƭ Frankfurt released a paper outlining its positioning in the area of tension between science’s social responsibility, academic freedom and freedom of opinion. Its main message: the university offers science a space for autonomy and creativity while simultaneously defending it against non-scientific interests. However, this autonomy also has its limits and requires responsible handling, both on the part of the university as well as its members and affiliates. The paper supplements the university's mission statement and specifies the rights and obligations both of the university and its academics, as derived from Germany’s Basic Law and other legal norms.
FRANKFURT. The paper reaffirms Ƭ’s self-image as a place where different academic views meet and struggle to make available groundbreaking knowledge. “Science thrives on dialog, discussion and discourse with stakeholders both inside and outside of academia. This is especially true for our university, which was founded by Frankfurt’s urban society for its urban society. In such a culture, academics have to withstand the possibility that others may publicly contradict them or protest against their academic events – as long as such criticism or process remains within the confines of the law. That being said, whenever academic freedom is threatened by statements or actions, it falls upon us as a university to protect it,” explains Ƭ President Prof. Enrico Schleiff. “It is important to remember that academic freedom does not apply to every statement made or event organized by scientists: There are indeed cases where they express their private opinions, for example on fields for which they are no experts, or pursue purely results-oriented ideological goals with an event. Such instances fall outside the domain of academic freedom and therefore outside the university's sphere of influence.”
The paper was developed to provide a better basis for dealing with public criticism of and protests against public events organized by Ƭ academics. “Many debates are highly polarized. If we want to pursue science in dialog with society, we must neither shy away from nor avoid it,” explains Schleiff. “As professors, we are trained for scientific discourse. But we also have to learn how to deal with criticism and arguments that are not of a scientific nature and how to remain confident in emotionally heated situations.” That is why the university has set up new training courses, including in facilitation and communication, to strengthen scientists’ skills, also during confrontational moments.
The paper was drawn up by an expert commission headed by legal scholar Prof. Matthias Jahn. In legal terms, it has the character of an administrative regulation that specifies standards: By explaining the applicable law, it serves as a binding guideline for all university members. It cannot, however, account for every individual decision. “The university makes its infrastructure available to its researchers so they can pursue science, not to carry out on-scientific activities and formats. Determining whether or not this is the case requires a case-by-case consideration, which also accounts for the standards of the respective subject culture,” Jahn explains. “The university’s management is not permitted to control the content of science, and controversies about the way in which knowledge is gained and interpreted fall under the scientific community’s responsibility. However, the university management can decide, for example, not to make rooms available for an event that is not subject to academic freedom if this decision is organizationally safeguarded in such a manner that a structural threat to academic freedom can be excluded. If academics consider such a decision to be wrong, they have recourse to the courts.” The courts, in turn, have to consider the specifics of the university's self-conception, explains Jahn, who has worked at various higher regional courts on a part-time basis for two decades.
The paper also clarifies that although academic freedom is guaranteed extensively in Germany’s Basic Law, this is no blank check guarantee for limitless scientific practice: It is possible to impose restrictions in individual cases in favor of goods that are considered to have greater merit, such as fundamental and human rights, freedom of education for students or the personal rights of third parties. If this is the case, the consequences can be severe: “Violations of this obligation (...) can constitute misconduct”, the paper states.
The administrative regulation specifying the standard was adopted by Ƭ’s Executive Board following earlier debates in both the Senate and the University Council. The draft was also discussed with representatives of Frankfurt municipality.
The official wording of the new administrative regulation:
Editor: Volker Schmidt, Head of PR & Communications Office, Theodor-W.-Adorno-Platz 1, 60323 Frankfurt am Main, Tel.: +49 (0)69/798-13035, v.schmidt@em.uni-frankfurt.de
Plans for joint research and teaching cooperation / Concert marks Ƭ’s 110th anniversary
Ƭ Frankfurt and the Jewish Academy operated by the Central Council of Jews in Germany [Zentralrat der Juden in Deutschland] are planning to deepen their cooperation. The relevant cooperation agreement was signed on October 30, 2024, by Central Council President Dr. Josef Schuster and Ƭ President Prof. Enrico Schleiff. The signing ceremony was followed by a reception and concert in the hr broadcasting hall, celebrating Ƭ’s 110th birthday.
FRANKFURT. The Jewish Academy is currently being set up in Frankfurt. Once operational, it will become an important center for the study of Jewish history and religion, culture and intellectual thought and both take up and enrich current debates – whether with regard to research, academic teaching or interaction with society. With this in mind, Ƭ and the Jewish Academy have entered into an “institutional cooperation in the sense of a permanent and consistent academic collaboration”, as outlined in the contract signed last Wednesday. Headquartered in Frankfurt, the Jewish Academy considers itself “an intellectual hub and center of attraction for Jews from Germany and Europe, members of other religious communities and interested members of the public who are curious about Jewish, intercultural, interreligious or universalist issues.”
“This cooperation builds on our university’s rich historical tradition as well as numerous present-day collaborations,” explained President Schleiff. “As an institution established by Frankfurt citizens for both urban and wider society, we owe our existence in large part to the city’s Jewish citizens of the time, who were among the founders of the endowed university in 1914. In the early 1920s, Franz Rosenzweig founded the Freie Jüdische Lehrhaus [Free Jewish Teaching House], which had many touch points with Frankfurt University. To this date we maintain a strong focus on Jewish religious studies, philosophy and Jewish studies, complemented by topics that extend beyond the boundaries of religion, including the dynamics of religion, cultures of remembrance or 'education after Auschwitz', to name just a few examples. Both this and the previous semester, we held a lecture series titled 'Antisemitism. Culture of Remembrance. Democracy’, together with the Central Council's education academy, the Jewish Academy’s predecessor – also with a view towards the historical amnesia that has unfortunately manifested itself since Hamas’ October 7 attack on Israel.”
“This cooperation is greatly important for the Jewish Academy and for Jewish life, not just in Frankfurt, but throughout Germany,” says Central Council President Dr. Josef Schuster. “It is here where common academic interests are lived, deepened and expanded. There already exist several projects that can now be cast in this new form. Universities are key to a modern society’s central nervous system, and their malfunctioning could plunge us all into the abyss. Ever since October 7, 2023, many German universities have become a setting for the darkest aspects of our society. It is partnerships like this that give us confidence that these forces will not prevail. By entering into this cooperation with the Jewish Academy, Ƭ Frankfurt is taking an important step together with Jewish life, thought and perspectives on our society in these turbulent times.”
“As a foundation university established on the initiative of many Jewish citizens, Ƭ Frankfurt has stood for equal opportunities and the integration of Jewish perspectives in academia and society for more than a century,” Hessian Minister President Boris Rhein said. “This cooperation with the Jewish Academy not only builds on and continues this tradition, it also deepens it in a special way and carries it into the future. In times like these, it is particularly important to truly live cultural and religious diversity and to strengthen our society’s democratic resilience by means of institutional cooperation.”
“This cooperation creates a very special bond between Ƭ Frankfurt, which owes its foundation largely to the efforts of large Jewish families, and the Jewish Academy run by the Central Council umbrella organization, which at the same time serves as the representative of Germany’s Jewish communities,” added Uwe Becker, Hessen’s state commissioner for Jewish life and the fight against antisemitism and a state secretary in the Hessian Ministry of Finance, who conveyed minister Rhein’s greetings at the signing ceremony. “It combines the tradition of the Jewish Teaching House with the underlying idea that teaching and learning be linked and anchored in society. I am certain that this will result in a think tank for Jewish and non-Jewish perspectives on our society’s development that is unique in Europe.”
The strategic goals and fields of action outlined in the agreement signed in Frankfurt include the continuation of existing as well as the initiation of further research collaborations to address new research questions and perspectives from a transdisciplinary perspective and to enrich discourse. In addition, the cooperation seeks to strengthen collaborative research and cooperation with a focus on top international research, the joint acquisition of funds, as well as mutual support in the acquisition of partners. Beyond that, it sets the stage for research-oriented teaching, jointly supervised doctoral theses, the opening of selected events and joint lecture series, workshops, seminars or conferences as well as publications, among others.
Prof. Mirjam Wenzel, Director of the Jewish Museum Frankfurt and honorary professor at Ƭ Frankfurt, also gave a keynote speech at the signing ceremony held on the premises of Hessischer Rundfunk (hr). Following the signing, Ƭ celebrated its 110th birthday in the hr broadcasting hall with a reception and a concert by the symphony orchestra of Tel Aviv University’s Buchmann-Mehta School of Music under the direction of renowned conductor Zubin Mehta, featuring works by Ludwig van Beethoven and Paul Ben-Haim. In addition to those present at the signing ceremony, other guests included Federal Minister of Education Bettina Stark-Watzinger and Dr. Ina Hartwig, Head of Frankfurt’s Department of Culture and Science. Tel Aviv University has been a partner of Ƭ Frankfurt since 1984. This special friendship was initiated by the joint Josef Buchmann Doctoral Scholarship Fund. The concert was a birthday present presented to Ƭ by honorary senator Dr. h.c. Josef Buchmann and Dr. h.c. Bareket Buchmann.
Editor: Volker Schmidt, Head of PR & Communications Office, Theodor-W.-Adorno-Platz 1, 60323 Frankfurt am Main, Tel.: +49 (0)69/798-13035, v.schmidt@em.uni-frankfurt.de
Toxins from remipede crabs in Mexican cenote caves have pharmacological potential // Species' habitat threatened
Zootoxins affect a wide range of physiological processes and are therefore of great interest for drug research. An international study led by Björn von Reumont of Ƭ Frankfurt has identified novel toxins from the cave-dwelling underwater crustacean Xibalbanus tulumensis that inhibit various ion channels. The discovery opens up promising pharmacological applications. The species is found exclusively in the cenote caves that were once sacred to the Maya.
FRANKFURT. Many animals use venoms for self-defense or hunting. The components of such venom, known as toxins, interfere with various physiological processes – which is also the reason why they are so interesting for the development of new pharmacological agents. While the venoms of some animal groups – including snakes, spiders, scorpions and insects – have already been quite well studied, the situation is entirely different for marine animal groups. Here, data exists only for individual animal species, meaning this group still holds great untapped potential.
It was only discovered a few years ago that there also exist venomous crustaceans, i.e. remipedes that look more like centipedes and live in marine underwater caves. A multidisciplinary research team led by Dr. Björn von Reumont, who first described the venom system in remipedes in 2014 and is currently a guest researcher at Ƭ Frankfurt, has now characterized a group of toxins from the Xibalbanus tulumensis remipede.
To that end, Reumont put together a team consisting of cooperation partners from Fraunhofer Institute for Translational Medicine (ITMP) within the framework of the LOEWE Center for Translational Biodiversity, as well as colleagues from the University of Leuven, from Cologne, Berlin and Munich – all of them also part of the European Venom Network (COST Action EUVEN).
The Xibalbanus tulumensis remipede lives in the cenotes which are the underwater cave systems on the Mexican Yucatan peninsula. The cave dweller injects the venom produced in its venom gland directly into its prey. This toxin contains a variety of components, including a new type of peptide, named xibalbine, after its crustacean producer. Some of these xibalbines contain a characteristic structural element that is familiar from other toxins, especially those produced by spiders: several amino acids (cysteines) of the peptide are bound to each other in such a manner that they form a knot-like structure. This in turn makes the peptides resistant to enzymes, heat and extreme pH values. Such knottins often act as neurotoxins, interacting with ion channels and paralyzing prey – an effect that has also been proposed for some xibalbines.
The study shows that all the xibalbine peptides tested by the cooperation partners' doctoral students – and in particular Xib1, Xib2 and Xib13 – effectively inhibit potassium channels in mammalian systems. “This inhibition is greatly important when it comes to developing drugs for a range of neurological diseases, including epilepsy," says von Reumont. Xib1 and Xib13 also exhibit the ability to inhibit voltage-gated sodium channels, such as those found in nerve or heart muscle cells. In addition, in the sensory neurons of higher mammals, the two peptides can activate two proteins – kinases PKA-II and ERK1/2 – involved in signal transduction. The latter suggests that they are involved in pain sensitization, which opens up new approaches in pain therapy.
Although the xibalbines' bioactivity is exemplary of the untapped potential of marine biodiversity, the production of drugs from animal venoms is a complex and time-consuming process. “Finding suitable candidates and comprehensively characterizing their effects, thus laying the foundation for safe and effective drugs, is only possible today in a large interdisciplinary team, as in the case of our study," says von Reumont.
Making matters more difficult is the fact that time is of the essence for the remipedes. Their habitat is under serious threat from the construction of the Tren Maya intercity railroad network, which cuts straight through the Yucatan Peninsula. “The cenotes are a highly sensitive ecosystem," explains von Reumont, who, as an experienced cave diver, has collected remipedes in Yucatan during several cave diving expeditions. “Our study highlights the importance of protecting biodiversity, not only for its ecological significance, but also for potential substances that could be of crucial importance to us humans."
Publication: Ernesto Lopes Pinheiro-Junior, Ehsan Alirahimi, Steve Peigneur, Jörg Isensee, Susanne Schiffmann, Pelin Erkoc, Robert Fürst, Andreas Vilcinskas, Tobias Sennoner, Ivan Koludarov, Benjamin-Florian Hempel, Jan Tytgat, Tim Hucho, Björn M von Reumont: Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling. BMC Biology 22, 164 (2024)
Picture download:
Captions:
(Entry)
Entrance to a cenote: Cenotes were once sacred to the Maya, as the karst caves were considered the entrance to the divine underworld. Photo: Björn M. von Reumont
(Diving)
Dive in the cenotes: The researchers collect the underwater crab Xibalbanus tulumensis, which only occurs here. Photo: Björn M. von Reumont
(Xibalbanus)
Toxic underwater crustacean: Xibalbanus tulumensis contains toxins that are suitable for the development of active substances against neurological diseases. Photo: Björn M. von Reumont
Further information
Dr. rer. nat. habil. Björn M. von Reumont
Guest researcher at the Research Group for Applied Bioinformatics/Prof. Ingo Ebersberger
Ƭ Frankfurt
Tel. +49(0)151-61997924
bmvr@reumont.net
Twitter/X: @BReumont @goetheuni @LOEWE_TBG @FraunhoferITMP @EUVENAction @KU_Leuven @UniCologne
Editor: Dr. Markus Bernards, Science Editor, PR & Communication Office, Theodor-W.-Adorno-Platz 1, 60323 Frankfurt am Main, Tel: -49 (0) 69 798-12498, Fax: +49 (0) 69 798-763 12531, bernards@em.uni-frankfurt.de
Award recognizes the discovery of a fundamental signaling pathway of innate immunity
Physician Andrea Ablasser from the École polytechnique fédérale de Lausanne, virologist Glen Barber from Ohio State University and biochemist Zhijian 'James' Chen from the University of Texas Southwestern Medical Center at Dallas will receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2025, the Scientific Council of the Paul Ehrlich Foundation announced today. The award honors the prizewinners' discovery of the cGAS-STING signaling pathway, i.e. the alarm system that sounds when, in the event of infection, cancer or cellular stress, DNA enters a cell's plasma. Once this happens, the police of the innate immune system is immediately called into action. Drugs interfering with this signaling pathway are currently under development.
FRANKFURT. It is extremely dangerous when, in response to either viral intruders or damage within the cell itself, DNA appears in the cytoplasm of a cell. Our immune system is then called upon to react immediately and initiate defensive measures. Just how it manages to do this is what the prizewinners researched and learned between 2008 and 2013 and have since been able to clarify more and more comprehensively. What they discovered are the stations and signals of an intracellular alarm system without which we could not survive. "The cGAS-STING signaling pathway is a foundation of our innate immune defense that has long been sought after," explains Prof. Thomas Boehm, chairman of the Paul Ehrlich Foundation's Scientific Council. "With their discovery, the award winners have opened up the possibility for medicine to treat infections, cancer and inflammatory diseases more effectively than before."
Ilya Mechnikov had already reported that nucleic acids such as DNA can trigger an immune reaction in 1908, when he was awarded the Nobel Prize for Medicine, which he shared with Paul Ehrlich. How this reaction takes place at the molecular-biological level only began to be clarified one hundred years later, in 2008, when Glen Barber and his team discovered a protein, that he called STING. This protein is anchored in the membrane of the cell's extensive tubular system, the endoplasmic reticulum (ER). Once an infection with DNA viruses occurs, STING commands certain genes in the cell nucleus to immediately start producing interferons. It is therefore, as the abbreviation says, a STimulator of INterferon Genes. The interferons are distributed in the surrounding tissue and stimulate the production of phagocytes and natural killer cells as well as other immune messengers.
How STING learned that DNA has appeared in the cytoplasm remained a mystery until 2012, when Zhijian 'James' Chen and his team solved it. With extraordinary biochemical sophistication, Chen isolated and identified a small ring-shaped molecule – cyclic guanosine monophosphate adenosine monophosphate (cGAMP) –, which consists of two nucleotides and is capable of activating STING, and later succeeded at doing the same for the enzyme cGAS, which catalyzes the formation of cGAMP. In 2013, Andrea Ablasser characterized cGAMP in detail and showed that its production and structure differ chemically from those of other dinucleotides. Ablasser was awarded the Paul Ehrlich and Ludwig Darmstaedter Early Career Award 2014 for this achievement.
The prizewinners' discoveries provide the following overall picture: The enzyme cGAS acts as a sensor for DNA in the cytoplasm. It clasps the DNA strands. Thereby it is enabled to change its conformation in such a way that it can produce the chemically unique messenger substance cGAMP from the molecules GTP and ATP, which are abundant in the cell's interior. cGAMP in turn triggers the transducer STING, which then brings other signal molecules into the alarm chain. The target of this relay is the genes in the cell nucleus, according to whose plan interferons and other immune messengers are produced.
Over the past decade, the three prizewinners have mapped the branches of the signaling pathway they discovered in ever greater detail, paying particular attention to the fact that the cGAS sensor does not differentiate between foreign and own DNA. This makes sense, considering that the cell's own DNA normally only occurs in the cell nucleus and in the mitochondria. If it leaks into the cytoplasm, as in cancer cells for example, cGAS has to kick in and switch on the immune defense. However, this is also risky because it can lead to unfounded immune attacks on the body – something against which our cells have effective protective mechanisms. However, the older we get, the more likely these mechanisms are to fail. This explains the rising incidence of non-infectious inflammations, also known as sterile inflammations, which are the basis of classic autoimmune, cardiovascular and neurodegenerative diseases, including Parkinson's. Sterile inflammations are characterized by an overactive cGAS-STING signaling pathway.
Substances that inhibit this signaling pathway therefore have great therapeutic potential and play an important role in the research of many pharmaceutical companies. Andrea Ablasser succeeded in synthesizing the first STING inhibitor in 2018.Agonists of this signaling pathway are not only being tested in vaccine development, but also as cancer drugs, and show strong preclinical antitumor effects in combination with checkpoint inhibitors.
Andrea Ablasser, born 1983, is Professor of Food Science at the École polytechnique fédérale de Lausanne in Switzerland.
Glen Barber, born 1962, is Professor in the Department of Surgery and Director of the Center for Innate Immunity and Inflammation, Pelonia Institute for Immuno-Oncology at the Ohio State University, Columbus, Ohio, USA.
Zhijian J. Chen, born 1966, is George L. MacGregor Distinguished Chair in Biomedical Science, Howard Hughes Medical Investigator and Professor of Molecular Biology at the University of Texas' Southwestern Medical Center in Dallas, USA.
Photos of the award winners are available for use and can be downloaded at .
Detailed background information "When DNA triggers an alarm" is available at
The prize will be awarded on March 14, 2025 at 5 p.m. by the Chairman of the Scientific Council of the Paul Ehrlich Foundation in Frankfurt's Paulskirche. We kindly ask you to take this into account when planning your schedule. Please do not hesitate to contact us if you have any questions.
Further information
Press Office Paul Ehrlich Foundation
Joachim Pietzsch
Phone: +49 (0)69 36007188
E-mail: j.pietzsch@wissenswort.com
Editorial office: Joachim Pietzsch / Dr. Markus Bernards, Science Communication Officer, PR & Communication Department, Theodor-W.-Adorno-Platz 1, 60323 Frankfurt am Main, Tel. +49 (0)69 798-12498, Fax +49 (0)69 798-763-12531, bernards@em.uni-frankfurt.de